ArticleJournal of cardiovascular electrophysiology2026
Digital Twin Guided Ventricular Tachycardia Ablation: Design and Rationale of the APOLO-VT Trial.
Article in Journal of cardiovascular electrophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundVT ablation reduces arrhythmic burden and ICD therapies, yet VT recurrence remains common. A key limitation is incomplete identification and durable elimination of the slow-conduction substrate. Structural imaging and ECGi provide complementary information but are not routinely integrated into a workflow-ready ablation strategy.
objectiveAPOLO-VT aims to evaluate the feasibility, safety, and clinical impact of an integrated multimodal mapping workflow combining noninvasive structural and functional substrate characterization using ECGi with invasive EAM to support VT ablation targeting and verification.
methodsAPOLO-VT is an interventional, prospective, single-center investigation enrolling 60 adults with structural heart disease undergoing VT ablation. Scar/border-zone characterization will be derived from LGE-CMR (or CT when contraindicated) and integrated with ECGi maps and invasive EAM. Noninvasively defined targets will be ablated, followed by S3-paced ECGi remapping; persistent deceleration zones will prompt additional ablation. If the S3-paced ECGi map is free of deceleration zones, programmed stimulation and an invasive S3-paced map will be performed to confirm endpoint achievement. Follow-up will be 12 months.
resultsThe primary endpoint is VT recurrence at 12 months. Secondary endpoints include acute non-inducibility, procedural efficiency, safety outcomes, mortality, and mechanistic concordance analyses.
conclusionsAPOLO-VT will provide prospective feasibility, safety, mechanistic, and exploratory outcome data on a standardized noninvasive-to-invasive multimodal strategy with iterative post-ablation functional noninvasive reassessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.